SUNNYVALE, Calif., Dec. 8, 2016 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) announced today that leading hospitals
in Europe and the United States are now treating patients
with the new Radixact™ Treatment Delivery System, fully integrated
with the new Accuray Precision™ Treatment Planning System and iDMS™
Data Management System. The first patient treatment in the world
was administered at the University Hospital Brussels (UZ Brussel)
in Belgium and in the United States at Froedtert & the
Medical College of Wisconsin Froedtert
Hospital in Milwaukee, Wisconsin,
part of the Froedtert & MCW Cancer Network.
The Radixact System in Europe
The University Hospital
Brussels (UZ Brussel) continues its legacy of innovation with the
installation of the Radixact System, software, and treatment of the
first patient worldwide. The smart new radiation therapy system
represents the next generation in TomoTherapy® treatment delivery,
significantly increasing treatment speed and ease of use. It
enables clinicians to treat a wide range of cancer cases, from
routine to complex, with precision and increased efficiency.
"We are proud and excited to be the first hospital in the world
to offer the new Radixact treatment option to our patients here in
Brussels. This advanced technology
represents another step forward toward optimal cancer care and
improved quality of life for patients," said Prof. Mark De Ridder, Head of the Radiation Oncology
Department, University Hospital Brussels (UZ Brussel, Vrije
Universiteit Brussel). "The first patient who underwent a Radixact
procedure received radiation to treat a metastatic mass in the
neck. We are now actively treating patients across a broad range of
cases and all treatments have gone smoothly. The precision software
is straightforward, the image quality on the system is improved and
dose delivery is efficient."
Additionally, patients in France will have access to the Radixact System
with its recent installation at the IUCT Oncopole – Institut
Universitaire du Cancer de Toulouse in Toulouse, France. The hospital's clinical
experts use the most current advances in cancer treatments to
develop personalized programs which improve the quality of care
they provide to patients.
The Radixact System in the United
States
Multiple sites in the United States are now equipped with the
Radixact System. Miami Cancer Institute, a part of Baptist Health
South Florida, and Froedtert & MCW Cancer Network are the first
to install the system.
Froedtert Hospital treated the first patient in the United States and is the only cancer
program in the Midwest currently offering treatment with the
advanced Radixact platform. Froedtert and MCW physicians selected
this system because it expands cancer treatment capabilities to
improve patients' outcomes and quality of life.
"For more than a decade, the Froedtert & MCW Cancer Network
has been at the forefront of the evolution of image-guided and
adaptive radiation therapy with the goal of providing more
personalized treatments," said Christopher
Schultz, MD, FACR, Medical College of
Wisconsin Professor and Chairman of the Department of
Radiation Oncology with the Froedtert & MCW Cancer Network.
"The new Radixact™ platform tightly integrates the treatment
planning function with the delivery of image-guided, highly
conformal treatments and importantly, provides the tools to perform
plan adaption when necessary."
The Radixact System was also chosen as the newest approach in
advanced radiation therapy treatment for the new state-of-the-art
$430 million facility at Miami Cancer
Institute. "Being the first in the Southeast to offer this
sophisticated technology helps to further expand the comprehensive
radiation treatments available to Miami Cancer Institute's patient
population, giving our unique and integrated department the
opportunity to deliver therapies best suited to treat a wide
variety of cancers," said Minesh P.
Mehta, M.D., Deputy Director and Chief of Radiation Oncology
at Miami Cancer Institute.
The Radixact® System leverages the TomoTherapy® System's
efficient, daily low-dose fan beam MVCT image guidance and unique
ring gantry architecture to deliver precise radiation treatments
for more patients, every day.
- The functionality effectively informs the radiation therapy
team's clinical decision-making throughout the course of each
patient's treatment, permitting precise and efficient treatment for
a wide range of cancer cases during initial treatment and
re-treatment.
- Adaptive therapy is more automated and efficient, enabling
clinicians to routinely incorporate adjustments to the treatment
planning and delivery process.
- Smart new tools can be used to monitor set-up technique each
day, thereby enabling highly consistent delivery, fraction by
fraction, patient by patient.
- The system is so precise that, should the cancer re-occur, the
patient can be re-treated on the Radixact System.
"We are excited about the early momentum in the adoption of this
new radiation therapy platform. Our customers have already treated
patients with the Radixact System, demonstrating their confidence
in its value as a mainstream treatment option," said Joshua H. Levine, president and chief executive
officer of Accuray. "These early adopters are leading the way for
other hospitals and clinics seeking an innovative and effective
technology to help them provide best-in-class radiation treatments
for their cancer patients now and into the future."
For further information on the Radixact System, visit
www.accuray.com.
Important Safety Information
For Important Safety Information please refer to
http://www.accuray.com/safety-statement-radiation-treatment
About Accuray
Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company
that develops, manufactures and sells precise, innovative tumor
treatment solutions that set the standard of care with the aim of
helping patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation
therapy and radiosurgery treatments. For more information, please
visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, market acceptance of our new technologies,
patient outcomes and Accuray's leadership position in radiation
oncology innovation and technologies. Forward-looking statements
are subject to risks and uncertainties that could cause actual
results to differ materially from expectations, including but not
limited to the risks detailed from time to time under the heading
"Risk Factors" in the company's report on Form 10-K, filed on
August 24, 2016, the company's report
on Form 10-Q, filed on November 1,
2016, and as updated periodically with the company's other
filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to
Accuray at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contacts
Beth Kaplan
Accuray
+1 (408) 789-4426
bkaplan@accuray.com
Jane Hauser
MSLGROUP
781-684-0770
accuray@mslgroup.com
Investor Contact
Doug Sherk
Investor Relations, EVC Group
+1 (415) 652-9100
dsherk@evcgroup.com
Photo- http://photos.prnewswire.com/prnh/20161207/446843
Logo -
http://photos.prnewswire.com/prnh/20160108/320376LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/first-cancer-patients-in-the-world-treated-with-the-smart-new-accuray-radixact-system-300374965.html
SOURCE Accuray Incorporated